Clinically significant drug-drug interactions between hepatitis C virus and HIV treatments

Topics in Antiviral Medicine

Volumn 24, Issue 3, 2016, Pages 106-110

  Kiser, Jennifer J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Coinfection; CYP3A4; Drug transporters; Drug drug interactions; HCV; Hepatitis C; HIV; HIV protease inhibitors; Metabolic enzymes; Tenofovir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ATAZANAVIR; BOSENTAN; CIPROFLOXACIN; CLARITHROMYCIN; CYTOCHROME P450 3A; DACLATASVIR; DARUNAVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; DEXAMETHASONE; DILTIAZEM; EFAVIRENZ; ELBASVIR PLUS GRAZOPREVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ERYTHROMYCIN; ETRAVIRINE; FLUCONAZOLE; FOSAMPRENAVIR; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LEDIPASVIR PLUS SOFOSBUVIR; LOPINAVIR; MODAFINIL; NAFCILLIN; NEFAZODONE; NELFINAVIR; POSACONAZOLE; RIBAVIRIN; RIFAMYCIN; RIFAPENTINE; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TENOFOVIR DISOPROXIL; VERAPAMIL; VORICONAZOLE; ANTIVIRUS AGENT;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CREATININE CLEARANCE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MIXED INFECTION; NONHUMAN; THROMBOCYTE COUNT; TRANSIENT ELASTOGRAPHY; VIRUS LOAD; COINFECTION; COMPLICATION; DRUG INTERACTION; HEPATITIS C, CHRONIC; HIV INFECTIONS;

ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 84994680318     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Khatri A, Dutta S, Dunbar M, et al. Evaluation of drug-drug interactions between direct-acting anti-hepatitis c virus combination regimens and the HIV-1 antiretroviral agents raltegravir, tenofovir, emtricitabine, efavirenz, and rilpivirine. Antimicrob Agents Chemother. 2016; 60(5): 2965-2971.
2. AbbVie. Viekira pak [prescribing information]. 2016. North Chicago, IL, AbbVie.
3. AASLD/IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. http://hcvguidelines.org/. Accessed on October 5, 2016.
4. Wyles D, Saag M, Trinh R et al. TURQUOISE-1 Part 1b: ombitasvir/paritaprevir/r+dasabuvir+RBV for HCV/HIV coinfection [Abstract 574]. Conference on Retroviruses and Opportunistic Infections. February 22-25, 2016; Boston, Massachusetts.
5. King JR, Khatri A, Trinh R et al. Pharmacokinetics of darunavir, ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in adults infected with hepatitis C virus (HCV) genotype 1 and human immunodeficiency virus (HIV) [Abstract 36]. 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. June 8-10, 2016; Washington, DC.
6. Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;[Epub ahead of print].
7. Terrault N, Zeuzem S, Di Bisceglie AM et al. (HCV-TARGET) - Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/ sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study. 66th Annual Meeting of the American Association for the Study of Liver Diseases. November 13-17, 2015; San Francisco, California.
8. Vivancos-Gallego MJ, Moreno A, Perez-Elias MJ et al. Real-life renal safety of boosted TDF in HIV/HCV patients on SOF/LDV [Abstract 452]. Conference on Retroviruses and Oppportunistic Infections. February 22-25, 2016; Boston, Massachusetts.
9. Garrison K, Custodio J, Pang P et al. Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor-based regimens [Abstract 71]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. May 26-28, 2015; Washington, DC.
10. Garimella T, Gandhi Y, Wang R et al. Daclatasvir exposure alone does not explain HCV relapse in HIV/HCV coinfected patients receiving daclatasvir plus sofosbuvir with ritonavir-boosted darunavir in the ALLY-2 study [Abstract 728]. 66th Annual Meeting of the American Association for the Study of Liver Diseases. November 13-17, 2016; Boston, Massachusetts.
11. Gandhi Y, Adamczyk R, Wang R et al. Assessment of drug-drug interactions between daclatasvir and darunavir/ritonavir or lopinavir/ ritonavir [80]. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. May 26-28, 2015; Washington, DC.
12. Wyles DL, Brau N, Kottilil S et al. Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study. European Association for the Study of the Liver (EASL), The International Liver Congress 2016. April 13-17, 2016; Barcelona, Spain.
13. Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol. 2014; 26(10): 1073-1082.
14. University of Liverpool. Hep drug interactions. http://www.hep-druginteractions.org/. Accessed on August 31, 2016.
15. Toronto General Hospital. Hepatitis C drug information for healthcare professionals. http://www.hcvdruginfo.ca/. Accessed on August 31, 2016.
16. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: considerations for antiretroviral use in patients with coinfections: hepatitis C (HCV)/HIV coinfection. https://aidsinfo.nih.gov/ guidelines/html/1/adult-and-adolescent-arv-guidelines/26/hiv-hcv. Accessed on August 31, 2016.